EUROFINS SCIENTIFIC (ERF.PA) Stock Fundamental Analysis
Europe - EPA:ERF - FR0014000MR3 - Common Stock
59.5 EUR
+0.12 (+0.2%)
ERF gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 19 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ERF get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on ERF. These ratings could make ERF a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year ERF was profitable.
ERF had a positive operating cash flow in the past year.
ERF had positive earnings in each of the past 5 years.
ERF had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of 3.54%, ERF perfoms like the industry average, outperforming 57.89% of the companies in the same industry.
With a decent Return On Equity value of 8.09%, ERF is doing good in the industry, outperforming 68.42% of the companies in the same industry.
ERF has a better Return On Invested Capital (9.79%) than 78.95% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ERF is in line with the industry average of 8.08%.
The 3 year average ROIC (8.70%) for ERF is below the current ROIC(9.79%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.54% | ||
| ROE | 8.09% | ||
| ROIC | 9.79% |
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
1.3 Margins
Looking at the Profit Margin, with a value of 5.44%, ERF is in line with its industry, outperforming 47.37% of the companies in the same industry.
ERF's Profit Margin has improved in the last couple of years.
ERF has a Operating Margin (15.59%) which is in line with its industry peers.
In the last couple of years the Operating Margin of ERF has grown nicely.
The Gross Margin of ERF (23.29%) is worse than 78.95% of its industry peers.
In the last couple of years the Gross Margin of ERF has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 5.44% | ||
| GM | 23.29% |
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ERF is creating some value.
Compared to 1 year ago, ERF has less shares outstanding
ERF has more shares outstanding than it did 5 years ago.
ERF has a better debt/assets ratio than last year.
2.2 Solvency
ERF has an Altman-Z score of 2.65. This is not the best score and indicates that ERF is in the grey zone with still only limited risk for bankruptcy at the moment.
ERF's Altman-Z score of 2.65 is in line compared to the rest of the industry. ERF outperforms 47.37% of its industry peers.
ERF has a debt to FCF ratio of 5.25. This is a neutral value as ERF would need 5.25 years to pay back of all of its debts.
ERF has a better Debt to FCF ratio (5.25) than 68.42% of its industry peers.
ERF has a Debt/Equity ratio of 0.77. This is a neutral value indicating ERF is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.77, ERF is not doing good in the industry: 68.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.25 | ||
| Altman-Z | 2.65 |
ROIC/WACC1.25
WACC7.85%
2.3 Liquidity
ERF has a Current Ratio of 1.26. This is a normal value and indicates that ERF is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.26, ERF perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
A Quick Ratio of 1.19 indicates that ERF should not have too much problems paying its short term obligations.
The Quick ratio of ERF (1.19) is better than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
ERF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.50%, which is quite good.
Measured over the past years, ERF shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.34% on average per year.
Looking at the last year, ERF shows a small growth in Revenue. The Revenue has grown by 2.53% in the last year.
Measured over the past years, ERF shows a quite strong growth in Revenue. The Revenue has been growing by 8.78% on average per year.
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
3.2 Future
Based on estimates for the next years, ERF will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.60% on average per year.
ERF is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.37% yearly.
EPS Next Y14.65%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPS Next 5Y15.6%
Revenue Next Year5.1%
Revenue Next 2Y5.44%
Revenue Next 3Y5.91%
Revenue Next 5Y7.37%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.53 indicates a correct valuation of ERF.
ERF's Price/Earnings ratio is rather cheap when compared to the industry. ERF is cheaper than 89.47% of the companies in the same industry.
ERF is valuated rather cheaply when we compare the Price/Earnings ratio to 25.91, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 14.94 indicates a correct valuation of ERF.
89.47% of the companies in the same industry are more expensive than ERF, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 34.57. ERF is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.53 | ||
| Fwd PE | 14.94 |
4.2 Price Multiples
ERF's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ERF is cheaper than 89.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ERF is valued cheaply inside the industry as 94.74% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.82 | ||
| EV/EBITDA | 8.34 |
4.3 Compensation for Growth
ERF's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ERF has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ERF's earnings are expected to grow with 14.00% in the coming years.
PEG (NY)1.13
PEG (5Y)0.9
EPS Next 2Y13.56%
EPS Next 3Y14%
5. Dividend
5.1 Amount
ERF has a Yearly Dividend Yield of 1.02%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 0.76, ERF pays a better dividend. On top of this ERF pays more dividend than 84.21% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, ERF's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.02% |
5.2 History
On average, the dividend of ERF grows each year by 16.51%, which is quite nice.
Dividend Growth(5Y)16.51%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
54.91% of the earnings are spent on dividend by ERF. This is a bit on the high side, but may be sustainable.
The dividend of ERF is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP54.91%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPA:ERF (11/13/2025, 7:00:00 PM)
59.5
+0.12 (+0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners37.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap10.84B
Revenue(TTM)6.89B
Net Income(TTM)374.80M
Analysts69.47
Price Target64.78 (8.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.02% |
Yearly Dividend0.52
Dividend Growth(5Y)16.51%
DP54.91%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.48%
PT rev (3m)-0.17%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.09%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)-0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.53 | ||
| Fwd PE | 14.94 | ||
| P/S | 1.57 | ||
| P/FCF | 13.82 | ||
| P/OCF | 8.24 | ||
| P/B | 2.34 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.34 |
EPS(TTM)3.6
EY6.05%
EPS(NY)3.98
Fwd EY6.69%
FCF(TTM)4.3
FCFY7.23%
OCF(TTM)7.22
OCFY12.13%
SpS37.84
BVpS25.45
TBVpS-3.69
PEG (NY)1.13
PEG (5Y)0.9
Graham Number45.4
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.54% | ||
| ROE | 8.09% | ||
| ROCE | 12.64% | ||
| ROIC | 9.79% | ||
| ROICexc | 10.74% | ||
| ROICexgc | 34.1% | ||
| OM | 15.59% | ||
| PM (TTM) | 5.44% | ||
| GM | 23.29% | ||
| FCFM | 11.37% |
ROA(3y)3.79%
ROA(5y)5.05%
ROE(3y)7.94%
ROE(5y)10.72%
ROIC(3y)8.7%
ROIC(5y)10.54%
ROICexc(3y)9.52%
ROICexc(5y)11.6%
ROICexgc(3y)31.02%
ROICexgc(5y)39.55%
ROCE(3y)11.31%
ROCE(5y)13.7%
ROICexgc growth 3Y-18.17%
ROICexgc growth 5Y3.78%
ROICexc growth 3Y-15.5%
ROICexc growth 5Y6.63%
OM growth 3Y-11.93%
OM growth 5Y3.56%
PM growth 3Y-23.05%
PM growth 5Y9.75%
GM growth 3Y-7.6%
GM growth 5Y1.83%
F-Score7
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 5.25 | ||
| Debt/EBITDA | 2.1 | ||
| Cap/Depr | 84.94% | ||
| Cap/Sales | 7.7% | ||
| Interest Coverage | 9.93 | ||
| Cash Conversion | 77.37% | ||
| Profit Quality | 209.21% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 2.65 |
F-Score7
WACC7.85%
ROIC/WACC1.25
Cap/Depr(3y)89.21%
Cap/Depr(5y)85.64%
Cap/Sales(3y)8.63%
Cap/Sales(5y)7.99%
Profit Quality(3y)162.79%
Profit Quality(5y)158.88%
High Growth Momentum
Growth
EPS 1Y (TTM)16.5%
EPS 3Y-21.42%
EPS 5Y18.34%
EPS Q2Q%19.61%
EPS Next Y14.65%
EPS Next 2Y13.56%
EPS Next 3Y14%
EPS Next 5Y15.6%
Revenue 1Y (TTM)2.53%
Revenue growth 3Y1.14%
Revenue growth 5Y8.78%
Sales Q2Q%5.64%
Revenue Next Year5.1%
Revenue Next 2Y5.44%
Revenue Next 3Y5.91%
Revenue Next 5Y7.37%
EBIT growth 1Y14.03%
EBIT growth 3Y-10.93%
EBIT growth 5Y12.66%
EBIT Next Year86.11%
EBIT Next 3Y30.34%
EBIT Next 5Y22.42%
FCF growth 1Y113.13%
FCF growth 3Y-7.69%
FCF growth 5Y25.62%
OCF growth 1Y31.31%
OCF growth 3Y-4.44%
OCF growth 5Y14.24%
EUROFINS SCIENTIFIC / ERF.PA FAQ
What is the ChartMill fundamental rating of EUROFINS SCIENTIFIC (ERF.PA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to ERF.PA.
Can you provide the valuation status for EUROFINS SCIENTIFIC?
ChartMill assigns a valuation rating of 7 / 10 to EUROFINS SCIENTIFIC (ERF.PA). This can be considered as Undervalued.
Can you provide the profitability details for EUROFINS SCIENTIFIC?
EUROFINS SCIENTIFIC (ERF.PA) has a profitability rating of 6 / 10.
How financially healthy is EUROFINS SCIENTIFIC?
The financial health rating of EUROFINS SCIENTIFIC (ERF.PA) is 5 / 10.
Is the dividend of EUROFINS SCIENTIFIC sustainable?
The dividend rating of EUROFINS SCIENTIFIC (ERF.PA) is 4 / 10 and the dividend payout ratio is 54.91%.